tetano
Editor, Senior Moderator
Commun Biol
. 2024 Feb 19;7(1):202.
doi: 10.1038/s42003-024-05805-6. Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2
Luis A Pérez-Jurado[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Alejandro Cáceres[SUP] #[/SUP][SUP] 4 5 [/SUP], Laura Balagué-Dobón[SUP] 4 5 [/SUP], Tonu Esko[SUP] 6 7 [/SUP], Miguel López de Heredia[SUP] 8 [/SUP], Inés Quintela[SUP] 8 9 [/SUP], Raquel Cruz[SUP] 8 9 10 11 [/SUP], Pablo Lapunzina[SUP] 8 12 13 [/SUP], Ángel Carracedo[SUP] 8 9 10 11 14 [/SUP]; SCOURGE Cohort Group; Juan R González[SUP] 15 16 17 [/SUP]
Collaborators, Affiliations
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people.
. 2024 Feb 19;7(1):202.
doi: 10.1038/s42003-024-05805-6. Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2
Luis A Pérez-Jurado[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Alejandro Cáceres[SUP] #[/SUP][SUP] 4 5 [/SUP], Laura Balagué-Dobón[SUP] 4 5 [/SUP], Tonu Esko[SUP] 6 7 [/SUP], Miguel López de Heredia[SUP] 8 [/SUP], Inés Quintela[SUP] 8 9 [/SUP], Raquel Cruz[SUP] 8 9 10 11 [/SUP], Pablo Lapunzina[SUP] 8 12 13 [/SUP], Ángel Carracedo[SUP] 8 9 10 11 14 [/SUP]; SCOURGE Cohort Group; Juan R González[SUP] 15 16 17 [/SUP]
Collaborators, Affiliations
- PMID: 38374351
- PMCID: PMC10876565
- DOI: 10.1038/s42003-024-05805-6
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people.